Levevitae® 500 mg (Levetiracetam 500 mg Film Coated Tablets)

국가: 말레이시아

언어: 영어

출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
02-07-2021
제품 특성 요약 제품 특성 요약 (SPC)
05-12-2020

유효 성분:

LEVETIRACETAM

제공처:

HEALOL PHARMACEUTICALS SDN. BHD.

INN (International Name):

LEVETIRACETAM

패키지 단위:

3 blisters x 10 Tablets; 10 blisters x 10 Tablets

Manufactured by:

Pharmathen S.A.

환자 정보 전단

                                LEVEVITAE
®
500MG
Levetiracetam (500mg) film-coated tablets
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What Levevitae is used for
2.
How Levevitae works
3.
Before you use Levevitae
4.
How to use Levevitae
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Levevitae
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
WHAT LEVEVITAE IS USED FOR
Levevitae is used:
• on its own in adults and adolescents
from 16 years of age with a certain type
of newly diagnosed epilepsy. Epilepsy is
a
condition
where
the
patients
have
repeated fits (seizures). Levetiracetam is
used for the epilepsy form in which the
fits initially affect only one side of the
brain,
but
could
thereafter
extend
to
larger areas on both sides of the brain
(partial onset seizures with or without
secondary generalization). Levevitae has
been
given
to
you
by
your
doctor
to
reduce the number of fits.
•
as
an
add-on
to
other
antiepileptic
medicines to treat:
- partial onset seizures with or without
secondary
generalization
in
adults
and
children
from
4
years
of
age
with
epilepsy.
- myoclonic seizures (short, shock-like
jerks of a muscle or group of muscles) in
adults and adolescents from 12 years of
age with juvenile myoclonic epilepsy
-
primary
generalized
tonic-clonic
seizures
(major
fits,
including
loss
of
consciousness)
in
adults
and
children
from
12
years
of
age
with
Idiopathic
Generalized Epilepsy.
HOW LEVEVITAE WORKS
•
Alone
(without
another
anti-epileptic
drug) in patients from 16 years of age
with newly diagnosed epilepsy, to treat
partial onset seizures with or without
secondary generalization.
•
Together
with
other
anti-epileptic
medicines to treat:
–
The partial onset seizures with or
without
generalization
in
patients
from 4 years of age.
–
Myoclonic seizures in patients 12
years
and
older
with
juvenile
myoclonic epilepsy.
–
Primary
generalised
tonic-clonic
seizures in patients from 12 years of
age
with
generalized
idiopathic
epilepsy.
BE
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 말레이어 02-07-2021

이 제품과 관련된 검색 알림